LIFECORE BIOMEDICAL, INC. Increase in Carrying Amount of Redeemable Preferred Stock
LIFECORE BIOMEDICAL, INC. (LFCR) reported Increase in Carrying Amount of Redeemable Preferred Stock of $47.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity
us-gaap:IncreaseInCarryingAmountOfRedeemablePreferredStock · last filed 2026-08-05
- LIFECORE BIOMEDICAL, INC. increase in carrying amount of redeemable preferred stock for the quarter ending 2026-06-30 was $47.00K.
- LIFECORE BIOMEDICAL, INC. increase in carrying amount of redeemable preferred stock for the quarter ending 2026-03-31 was $47.00K.
- LIFECORE BIOMEDICAL, INC. increase in carrying amount of redeemable preferred stock for the quarter ending 2025-09-30 was $48.00K.
- LIFECORE BIOMEDICAL, INC. increase in carrying amount of redeemable preferred stock for the quarter ending 2025-05-25 was $48.00K, a 0.00% change year-over-year.
- LIFECORE BIOMEDICAL, INC. increase in carrying amount of redeemable preferred stock for fiscal 2025 was $192.00K, a 0.52% increase from fiscal 2024.
- LIFECORE BIOMEDICAL, INC. increase in carrying amount of redeemable preferred stock for fiscal 2024 was $191.00K, a 161.64% increase from fiscal 2023.
- LIFECORE BIOMEDICAL, INC. increase in carrying amount of redeemable preferred stock for fiscal 2023 was $73.00K.
| Period end | Increase in Carrying Amount of Redeemable Preferred Stock 3 month | Increase in Carrying Amount of Redeemable Preferred Stock 6 month | Increase in Carrying Amount of Redeemable Preferred Stock 7 month | Increase in Carrying Amount of Redeemable Preferred Stock 9 month | Increase in Carrying Amount of Redeemable Preferred Stock 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $47.00K 10-Q · filed 2026-08-05 | $94.00K 10-Q · filed 2026-08-05 | |||
| 2026-03-31 | $47.00K 10-Q · filed 2026-05-06 | ||||
| 2025-12-31 | $117.00K 10-KT · filed 2026-03-16 | ||||
| 2025-09-30 | $48.00K 10-Q · filed 2025-11-06 | ||||
| 2025-05-25 | $48.00K 10-Q · filed 2026-08-05 | $96.00K 10-Q · filed 2026-08-05 | $144.00K derived: sum of 3 quarters · filed 2026-08-05 | $192.00K 10-KT · filed 2026-03-16 | |
| 2025-02-23 | $48.00K 10-Q · filed 2026-05-06 | $96.00K derived: sum of 2 quarters · filed 2026-05-06 | $144.00K 10-Q · filed 2025-04-03 | $192.00K derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-11-24 | $48.00K 10-Q · filed 2025-01-02 | $96.00K derived: sum of 2 quarters · filed 2025-11-06 | $144.00K derived: sum of 3 quarters · filed 2026-03-16 | $192.00K derived: sum of 4 quarters · filed 2026-03-16 | |
| 2024-08-25 | $48.00K 10-Q · filed 2025-11-06 | $96.00K derived: sum of 2 quarters · filed 2026-03-16 | $144.00K derived: sum of 3 quarters · filed 2026-03-16 | $191.00K derived: sum of 4 quarters · filed 2026-03-16 | |
| 2024-05-26 | $48.00K derived: 10-KT 12 month − 10-Q 9 month · filed 2026-03-16 | $96.00K derived: sum of 2 quarters · filed 2026-03-16 | $143.00K derived: sum of 3 quarters · filed 2026-03-16 | $191.00K 10-KT · filed 2026-03-16 | |
| 2024-02-25 | $48.00K 10-Q · filed 2025-04-03 | $95.00K derived: sum of 2 quarters · filed 2025-04-03 | $143.00K 10-Q · filed 2025-04-03 | ||
| 2023-11-26 | $47.00K 10-Q · filed 2025-01-02 | $95.00K derived: sum of 2 quarters · filed 2025-01-02 | |||
| 2023-08-27 | $48.00K 10-Q · filed 2025-01-02 | ||||
| 2023-05-28 | $73.00K 10-K · filed 2024-08-26 | ||||
| 2023-02-26 | $25.00K 10-Q · filed 2024-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |